Filing Details
Viridian Therapeutics, Inc.\DE (NASDAQ:VRDN) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 04, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:VRDN
Viridian Therapeutics, Inc.\DE (VRDN) Files Quarterly Report for Q0
Viridian Therapeutics, Inc.\DE (NASDAQ:VRDN) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 04, 2026.
At publication ·
What changed
Viridian Therapeutics, Inc.\DE (NASDAQ:VRDN) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Viridian Therapeutics filed its quarterly report on November 4, 2026, with the SEC.
- The healthcare company's stock trades at $25.15 with a market capitalization of $2.6 billion.
- The 10-Q filing contains unaudited financial statements and management commentary on recent business performance and risks.
Market Context
Viridian Therapeutics, Inc.\DE's stock currently trades at $25.15 with a market capitalization of $2.6B.
The 10-Q provides Viridian Therapeutics, Inc.\DE's quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Viridian Therapeutics, Inc.\DE are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View VRDN Stock Page
Frequently Asked Questions
Where can I read VRDN's SEC filings?
Browse all filings on our VRDN SEC filings page.
What types of SEC filings does Viridian Therapeutics, Inc.\DE file?
Public companies like Viridian Therapeutics, Inc.\DE file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.